Movers and SHAKERS
|Current Price||$59.93 ↑ 17.50|
|52wk Range||$19.38 - $48.82|
|ADVANCED MARKET DATA|
Advanced Market DataAxsome Therapeutics Inc. (AXSM)
New York, NY 10004
Axsome Therapeutics Inc is a United States-based healthcare service provider. As a pre-clinical therapeutics developer, the company attends primarily to central nervous system disorders such as Alzheimer's. Its product portfolio consists of novel drugs like the AXS-02 (disodium zoledronate tetrahydrate), which is an oral, non-opioid therapeutic for chronic pain and the AXS-05, which is a fixed-dose combination of dextromethorphan and bupropion. The AXS-02 addresses pain in over three conditions, such as complex regional pain syndrome, knee osteoarthritis and chronic low back pain. The AXS-05 on the other hand, treats resistant depression and agitation in patients with Alzheimer's disease. Both the products have passed the preclinical, Phase 1 and Phase 2 stages of development.
Shares of the commercial-stage healthcare company Axsome Therapeutics (NASDAQ: AXSM) were up by a handsome 31.4%, on heavy volume, as of 9:53 a.m. ET Friday. The stock price of the specialist in central nervous system disorders is shooting higher today in response to the Food and Drug Administration's (FDA) approval of its major depressive disorder (MDD) drug Auvelity.
Auvelity has been under review with the FDA for well over a year at this point. The drug's review took longer than expected due to issues with the analytical methods in the Chemistry, Manufacturing, and Controls section of its regulatory application.
For further details see:Why Axsome Therapeutics Stock Is Crushing It Today
Axsome Therapeutics Inc. Corporate Filings
Axsome Therapeutics Inc. Corporate Events
Axsome Therapeutics Inc. Press Releases / News Feed
No reports available